Innate Pharma
IPHA | NASDAQ
$1.41
+$0.03 (+2.17%)
At close: Nov 16, 2026, 4:00 PM ET
$1.44
+$0.03 (+2.12%)
After-hours:
Nov 16, 2026, 4:19 PM ET
+2.17%
(1D)No price chart data available for 1D timeframe.
Rating
26.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #886/1021 (Top 87%)
Key Statistics
Market Data
Market Cap $150.85M
1D Range
1.31 1.41
52W Range
1.17 2.54
Valuation (TTM)
PE -2.37
PB -3.26
EV/EBITDA -2.85
Valuation (NTM)
Forward PE 40.01
Forward PEG 0.03
Price Target $7.00
Cash Flow
FCF Yield -32.7%
SBC Adj. FCF Yield -32.7%
SBC Impact N/A
Margins
Gross Margin 1770.3%
Operating Margin -1309.4%
FCF Margin -1250.7%
Growth (CAGR)
Revenue 3Y | 5Y -59.5% |
-38.6%
Dil EPS 3Y | 5Y -26.8% |
12.3%
FCF 3Y | 5Y -29.0% |
21.9%
Returns
ROA -136.7%
ROE 152.6%
ROIC -380.7%
Financial Health
Net Debt
€9.26M ($10.58M)
Current Ratio 0.60
Interest Coverage -17.47
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. T...
Sector Healthcare
Industry Biotechnology
Employees 163
IPO Date Oct 17, 2019
Website www.innate-pharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.24
Beat +18.12%
YoY:
+18.58% REV
$6.5M
Beat +2.38%
YoY:
+12.94%Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$7.00
Upside
+396.45%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove IPHA